HempeJMGomezRMcCarterRJ. High and low hemoglobin glycation phenotypes in type 1 diabetes: A challenge for interpretation of glycemic control. J Diabetes Complications2002; 16: 313–320.
2.
McCarterRJHempeJMGomezR. Biological variation in HbA1c predicts risk of retinopathy and nephropathy in type 1 diabetes. Diabetes Care2004; 27: 1259–1264.
3.
BrownleeM. Advanced protein glycosylation in diabetes and aging. Annu Rev Med1995; 46: 223–234.
4.
GersteinHCMillerME. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med2008; 358: 2545–2559.
5.
BondsDEMillerMEBergenstalRM. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: Retrospective epidemiological analysis of the ACCORD study. BMJ2010; 340: b4909–b4909.
6.
MillerMEBondsDEGersteinHC. The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: Post hoc epidemiological analysis of the ACCORD study. BMJ2010; 340: b5444–b5444.
7.
HempeJMLiuSMyersL. The hemoglobin glycation index identifies subpopulations with harms or benefits from intensive treatment in the ACCORD trial. Diabetes Care2015; 38: 1067–1074.
8.
Van Steen SC, Schrieks IC, Hoekstra JB, et al. The haemoglobin glycation index as predictor of diabetes-related complications in the AleCardio trial. Eur J Prev Cardiol. Epub ahead of print 10 February 2017; DOI: 10.1177/2047487317692664.
9.
LincoffAMTardifJ-CSchwartzGG. Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: The AleCardio randomized clinical trial. JAMA2014; 311: 1515–1525.
10.
Ahn CH, Min SH, Lee D-W, et al. Hemoglobin glycation index is associated with cardiovascular diseases in people with impaired glucose metabolism. J Clin Endocrinol Metab. Epub ahead of print 23 May 2017. DOI: 10.1210/jc.2017-00191.
